Gamida Cell to Host Conference Call and Webcast to Review Data from NAM-NK and NiCord® Programs Being Presented at 2019 TCT Annual Meeting
A live webcast of the conference call can be accessed in the Investors section of Gamida Cell’s website at www.gamida-cell.com. To participate in the conference call, please dial 1-866-930-5560 (domestic) or 1-409-216-0605 (international) five minutes prior to start time. The conference ID number is 9462948. An archived version of the webcast will be available on Gamida Cell’s website for 30 days.
Details about the presentations are as follows:
Time:
Title: First-in-Human Phase I Study of
Nicotinamide-Expanded Related Donor Natural Killer Cells for the
Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma and Multiple
Myeloma
Poster Number: 242
Lead Author: Veronika
Bachanova, M.D., Ph.D., associate professor of medicine, division of
hematology, oncology and transplantation,
Location:
Time:
Title: Ex Vivo Nicotinamide-Expanded
(NAM-Expanded) Unrelated Cord Blood Transplantation (UCB) for Refractory
Severe Aplastic Anemia Results in Rapid Engraftment and Expedites Immune
Recovery
Poster Number: 295
Lead Author:
Location:
Time:
Title: Rapid and Robust CD4+ and CD8+ T-, NK-,
B-Cell, Dendritic Cell, and Monocyte Reconstitution after
Nicotinamide-Expanded Cord Blood Transplantation
Abstract
Number: 69
Lead Author:
Location: Hilton
Americas Houston, Grand Ballroom G
Abstracts are available on the 2019TCT Meetings of ASBMT and CIBMTR website.
About NAM-NK
About NiCord
NiCord, the company’s lead clinical program, is
under development as a universal bone marrow transplant solution for
patients with high-risk hematologic malignancies. NiCord has been
granted Breakthrough Therapy designation by the
NAM-NK and NiCord are investigational therapies, and their safety and
efficacy have not been evaluated by the
About
Cautionary Note Regarding Forward Looking Statements
This
press release contains forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995,
including with respect to the presentations of data related to the Phase
1 study of NAM-NK, the Phase 1/2 study of NiCord for the treatment of
hematologic malignancies, and the Phase 1/2 study of NiCord for the
treatment of severe aplastic anemia, which statements are subject to a
number of risks, uncertainties and assumptions, including, but not
limited to the scope, progress and expansion of Gamida Cell’s studies.
In light of these risks and uncertainties, and other risks and
uncertainties that are described in the Risk Factors section of our
Registration Statement on Form F-1 filed with the
1 ClinicalTrials.gov identifier NCT03019666.
2
ClinicalTrials.gov identifier NCT02730299.
3 ClinicalTrials.gov
identifier NCT03173937.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190214005042/en/
Source:
Jaren Irene Madden
jaren@gamida-cell.com
1-617-286-6264
Media
Inquiries
Krystle Gibbs
krystle@tenbridgecommunications.com
508-479-6358